Capmatinib Hydrochloride
Capmatinib Hydrochloride is a targeted therapy medication used to treat adults with metastatic non-small cell lung cancer (NSCLC) that has specific genetic mutations. It is specifically indicated for patients whose tumors have MET (mesenchymal-epithelial transition factor) exon 14 skipping alterations. This oral medication works by inhibiting the MET tyrosine kinase, which is involved in cancer cell growth and spread.
Capmatinib Hydrochloride is an oral targeted therapy for MET-positive metastatic non-small cell lung cancer.
Key facts at a glance
- RxNorm
- 2362259
- Generic
- Capmatinib Hydrochloride
- Class
- pin-variant
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Capmatinib Hydrochloride is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have MET exon 14 skipping mutations. This is typically determined through biomarker testing before treatment initiation.
Capmatinib is a MET tyrosine kinase inhibitor. It works by blocking the activity of the MET protein, which is a receptor tyrosine kinase involved in cell signaling pathways that promote cancer cell growth, survival, and spread. By inhibiting MET, the medication helps slow or stop the progression of tumors with MET alterations.
Capmatinib is an oral medication taken twice daily with or without food. Common side effects may include edema, fatigue, nausea, and liver enzyme elevations. Patients should have their lung cancer tested for MET exon 14 skipping mutations prior to treatment. Regular monitoring of liver function and other parameters may be required during treatment. Healthcare providers should be consulted for complete safety information and potential drug interactions.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy